B
Bruno Bockorny
Researcher at Beth Israel Deaconess Medical Center
Publications - 50
Citations - 1071
Bruno Bockorny is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 13, co-authored 40 publications receiving 662 citations. Previous affiliations of Bruno Bockorny include University of Connecticut Health Center & Hartford Hospital.
Papers
More filters
Journal ArticleDOI
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Bruno Bockorny,Bruno Bockorny,Valerya Semenisty,Teresa Macarulla,Erkut Borazanci,Brian M. Wolpin,Salomon M. Stemmer,Salomon M. Stemmer,Talia Golan,Talia Golan,Ravit Geva,Ravit Geva,Mitesh J. Borad,Katrina S. Pedersen,Joon Oh Park,Robert A. Ramirez,David Gutierrez Abad,Jaime Feliu,Andrés Muñoz,Mariano Ponz-Sarvise,Amnon Peled,Tzipora M. Lustig,Osnat Bohana-Kashtan,Stephen M. Shaw,Ella Sorani,Marya F. Chaney,Shaul Kadosh,Abi Vainstein Haras,Daniel D. Von Hoff,Manuel Hidalgo,Manuel Hidalgo +30 more
TL;DR: Results from the phase IIa COMBAT trial combining CXCR4 and PD-1 inhibition in patients with metastatic cancer show encouraging clinical responses in association with enhanced antitumor immune activation.
Journal ArticleDOI
Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature
TL;DR: Patients in whom CLL had been treated with fludarabine had a shorter survival after transformation compared to the ones not treated with this agent, and the role of immunosuppression and Epstein–Barr virus infection in the aetiopathogenesis of this entity remains to be clarified.
Journal ArticleDOI
Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression
Maria Rusan,Maria Rusan,Maria Rusan,Kapsok Li,Kapsok Li,Yvonne Y. Li,Yvonne Y. Li,Camilla L. Christensen,Brian J. Abraham,Nicholas Kwiatkowski,Nicholas Kwiatkowski,Kevin A. Buczkowski,Bruno Bockorny,Bruno Bockorny,Bruno Bockorny,Ting Chen,Shuai Li,Kevin Rhee,Haikuo Zhang,Wankun Chen,Wankun Chen,Hideki Terai,Tiffany Tavares,Alan L. Leggett,Tianxia Li,Yichen Wang,Tinghu Zhang,Tae-Jung Kim,Tae-Jung Kim,Sook Hee Hong,Neermala Poudel-Neupane,Michael Silkes,Tenny Mudianto,Li Tan,Takeshi Shimamura,Matthew Meyerson,Matthew Meyerson,Adam J. Bass,Adam J. Bass,Adam J. Bass,Hideo Watanabe,Nathanael S. Gray,Richard A. Young,Kwok-Kin Wong,Peter S. Hammerman,Peter S. Hammerman,Peter S. Hammerman +46 more
TL;DR: Carugo et al. as discussed by the authors showed that the addition of a newly identified CDK7/12 inhibitor, THZ1, to targeted therapy enhances cell killing and impedes the emergence of drug-resistant cell populations in diverse cellular and in vivo cancer models.
Journal ArticleDOI
Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature.
TL;DR: The case of a 56-year-old woman with a medical history of well-controlled hypertension who was newly diagnosed with International Staging System stage I multiple myeloma is reviewed, the first case where pericardial effusion and mitral regurgitation were described after bortezomib treatment.
Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression
Maria Rusan,Maria Rusan,Maria Rusan,Kapsok Li,Kapsok Li,Yvonne Y. Li,Yvonne Y. Li,Camilla L. Christensen,Brian J. Abraham,Nicholas Kwiatkowski,Nicholas Kwiatkowski,Kevin A. Buczkowski,Bruno Bockorny,Bruno Bockorny,Bruno Bockorny,Ting Chen,Shuai Li,Kevin Rhee,Haikuo Zhang,Wankun Chen,Wankun Chen,Hideki Terai,Tiffany Tavares,Alan L. Leggett,Tianxia Li,Yichen Wang,Tinghu Zhang,Tae-Jung Kim,Tae-Jung Kim,Sook Hee Hong,Neermala Poudel-Neupane,Michael Silkes,Tenny Mudianto,Li Tan,Takeshi Shimamura,Matthew Meyerson,Matthew Meyerson,Adam J. Bass,Adam J. Bass,Adam J. Bass,Hideo Watanabe,Nathanael S. Gray,Richard A. Young,Kwok-Kin Wong,Peter S. Hammerman,Peter S. Hammerman,Peter S. Hammerman +46 more
TL;DR: It is shown that the addition of a newly identified CDK7/12 inhibitor, THZ1, to targeted therapy enhances cell killing and impedes the emergence of drug-resistant cell populations in diverse cellular and in vivo cancer models.